Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Beaulieu, Laval
Christian Beaulieu, Laval CA
| Patent application number | Description | Published |
|---|---|---|
| 20080227758 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5h)-Furanones as Cyclooxygenase-2 Inhibitors - The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. | 09-18-2008 |
| 20100179173 | SUBSTITUTED FUSED PYRIMIDINES AS ANTAGONISTS OF GPR105 ACTIVITY - Fused pyrimidine compounds of structural formula (I) are effective as antagonists of the biological activity of the GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and Metabolic Syndrome. | 07-15-2010 |
| 20100305056 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE - Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, strongyloidiasis, trichostrongyliasis, trichomoniasis or cestodiasis. Compounds of formula I of the invention are capable of treating and/or preventing the above-identified diseases: | 12-02-2010 |
Josee Beaulieu, Laval CA
| Patent application number | Description | Published |
|---|---|---|
| 20110002994 | METHOD OF REGULATING THE TH17 PATHWAY AND ITS ASSOCIATED METABOLIC IMPACT - It is disclosed a method of immunomodulating an immune response in a subject comprising administering to a subject a malleable protein matrix (MPM), from fermented whey, in an amount effective to modulate the biological activity of Th17 cells, and its associated metabolic pathway, for a preventative or a therapeutic purpose of a variety of health applications in the field of immunity or obesity related diseases. | 01-06-2011 |
Patrick Beaulieu, Laval CA
| Patent application number | Description | Published |
|---|---|---|
| 20080207590 | Inhibitors of Histone Deacetylase - This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) | 08-28-2008 |
| 20110021771 | INHIBITORS OF HISTONE DEACETYLASE - This invention relates to compounds and methods for the inhibition of HDAC enzymatic activity. More particularly, the invention provides for compounds of formula (I), (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein L, M, n, R, W, X and Y are as defined in the specification. | 01-27-2011 |
Pierre L. Beaulieu, Laval CA
| Patent application number | Description | Published |
|---|---|---|
| 20100190779 | VIRAL POLYMERASE INHIBITORS - Compounds of formula I: | 07-29-2010 |
| 20100286131 | VIRAL POLYMERASE INHIBITORS - Compounds of formula I: | 11-11-2010 |
Pierre Louis Beaulieu, Laval CA
| Patent application number | Description | Published |
|---|---|---|
| 20090087409 | Viral Polymerase Inhibitors - An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: | 04-02-2009 |